Farideh Sadat Esbah Zavareh1, Mahboubeh Hadiipour2, Reza Kalantari2, Somayeh Mousavi2, Negah Tavakolifard3, Hossein Yousofi Darani∗2
Despite all advances in cancer treatment methods, failure of treatment is a major concern. This failure can be caused by tumor environment made by tumor cells and prevents immune system to reach neoplastic cells. So, cancer immunotherapy and target therapy are in the focus of scientists. Due to the inverse relationship shown between parasites and cancer, parasites are a candidate for use in cancer immunotherapy. Toxoplasma gondii is an intracellular parasite invades many cells of vertebrae spices but make symptoms only in fetus and immuno-deficient person. Studies have shown T. gondii can stimulate immune system against neoplastic cells and break fort of tumor environment. In this experimental work, Colon cancer bearing mice randomly divided into three groups. Groups 1 and 2 were injected with either lysate or irradiated tachyzoite of T. gondii respectively. The third group were left intact as control group. Our resulted data showed that in irradiated tachyzoite or lysate treated groups there was a significant reduction in tumor growth in comparison with control group. However, the difference in survival time was not statistically significant. In conclusion, treatment with T. gondii antigens resulted in suppression of tumor growth.
Keywords: Toxoplasma gondii; Cancer; Immunotherapy; Tumor; Mouse model
Copyright © 2021 by The American Society for BioMedicine and BM-Publisher, Inc.
- 1. Toxoplasma gondii. Galveston (TX): University of Texas Medical Branch at Galveston; 1996.2. Dubey JP, Lindsay DS, Speer CA. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clinical Microbiology Reviews 1998;11: 267-99.
3. Darani HY, Yousefi M. Parasites and cancers: Parasite antigens as possible targets for cancer immunotherapy. Future Oncology 2012; 8: 1529-35.
4. World Health Organization. All cancers, Source: Globocan 2018 [Internet]. Vol. 876. 2018. Available from: http://gco.iarc.fr/today
5. Fox BA, Butler KL, Guevara RB, Bzik DJ. Cancer therapy in a microbial bottle: Uncorking the novel biology of the protozoan Toxoplasma gondii. PLOS Pathog [Internet]. 2017; 13(9): e1006523. https://doi.org/10.1371/journal.ppat.1006523
6. Fox BA, Sanders KL, Bzik DJ. Non-replicating Toxoplasma gondii reverses tumor-associated immunosuppression. 2013;(November):11-3. https://doi.org/10.4161/onci.26296
7. Sanders KL, Fox BA, Bzik DJ. Attenuated Toxoplasma gondii therapy of disseminated pancreatic cancer generates long-lasting immunity to pancreatic cancer. Oncoimmunology [Internet]. 2016; 5(4): 1-5.
8. Mohamadi F, Shakibapour M, Sharafi SM, Andalib AR, Tolouei S, Darani HY. Anti-toxoplasma gondii antibodies attach to mouse cancer cell lines but not normal mouse lymphocytes. Biomed Reports. 2019; 10(3): 183-8.
9. Mercer HL, Snyder LM, Doherty CM, Fox BA, Bzik DJ, Denkers EY. Toxoplasma gondii dense granule protein GRA24 drives MyD88-independent p38 MAPK activation, IL-12 production and induction of protective immunity. PLoS Pathog [Internet]. 2020;16(5):1-24. https://doi.org/10.1371/journal.ppat.1008572
10. Darani HY, Shirzad H, Mansoori F, Zabardast N, Mahmoodzadeh M. Effects of Toxoplasma gondii and Toxocara canis antigens on WEHI-164 fibrosarcoma growth in a mouse model. Korean J Parasitol. 2009;47(2):175-7.
11. Daneshpour S, Bahadoran M, Hejazi SH, Eskandarian AA, Mahmoudzadeh M, Darani HY. Common antigens between hydatid cyst and cancers. Adv Biomed Res [Internet]. 2016;5:9.
12. Baird JR, Fox BA, Sanders KL, Lizotte PH, Cubillos-Ruiz JR, Scarlett UK, et al. Avirulent toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. Cancer Res. 2013;73(13):3842-51. https://doi.org/10.1158/0008-5472.CAN-12-1974
13. Sanders KL, Fox BA, Bzik DJ. Attenuated Toxoplasma gondii stimulates immunity to pancreatic cancer by manipulation of myeloid cell populations. Cancer Immunol Res. 2015;3(8):891-901.
14. Kim JS, Lee D, Kim D, Mun SJ, Cho E, Son W, et al. Toxoplasma gondii GRA8-derived peptide immunotherapy improves tumor targeting of colorectal cancer. Oncotarget. 2020;11(1):62-73.
15. Jiao YM, Zhang L, Ge YY, Liang YJ, Yong W. Effects of excreted/secreted antigens of Toxoplasma gondii on CD4+ CD25+ Foxp3+ T cells and NK cells of melanoma-bearing mice. Chinese journal of schistosomiasis control. 2011;23(3):3016.
16. Suzuki Y, Muto M, Kobayashi A. Antitumor effect of formalin-fixed Toxoplasma gondii organisms on EL4 lymphoma in Toxoplasma-infected mice. J Biol Response Mod. 1986;5(4):288-93.
17. Miyahara K, Honda U, Tose S, Sakurai H, Igarashi I, Saito A, et al. Therapeutic effects of Toxoplasma lysate antigen on 20- methylcholanthrene-induced BALB/c mouse tumors. J Vet Med Sci. 1992;54(1):7-12.
READ THE FULL ARTICLE
- For any technique error please contact us
American Journal of BioMedicine Volume 9, Issue 4, pages 168-176
Received July 14, 2021; revised September 21, 2021; accepted October 18, 2021; published November 18, 2021
How to cite this article
Zavareh FS, Hadiipour M, Kalantari R, Mousavi Z, Tavakolifard N, Darani HY. Effect of Toxoplasma gondii on colon cancer growth in mouse model. American Journal of BioMedicine 2021;9(2):168-176.